TL; DR
-
Trump’s new memo cracks down on pharma DTC ads—TV, digital, social, influencers, and online pharmacies are all in scope.
-
By the end of this year, some brands will lose up to 40% of their patient acquisition pipeline.
-
Activist investors and proxy advisors are already scrutinizing marketing ROI; your board will follow.
-
Brands with integrated PESO Model® strategies see 23% lower acquisition costs and 31% higher lifetime value.
-
Several major pharma companies are already shifting budgets and building PESO infrastructure now.
-
If you move today, by January you’ll have PESO in place—and by March, you’ll be taking market share. (And we can help you with that!)
Pharma Needs the PESO Model©
Ten billion dollars in pharma advertising just became a whole lot less effective. By the end of this year, someone in your category will lose 40% of their patient acquisition pipeline. The only question is whether it’s you or your competitor.
Your top-performing campaign—the one driving 60% of new patient starts—suddenly needs 45 seconds of risk disclosure in a 60-second spot. Your cost per acquisition triples overnight. Your board wants answers.
Meanwhile, your competitor, who diversified their mix six months ago, swoops in and captures your market share while you’re still rewriting copy and reshooting ads.
And it isn’t just TV commercials that are under the microscope. It’s social, digital, influencers, and even online pharmacies.
The “refer to our website” loophole you’ve leaned on? Gone. Enforcement letters are already going out. If you think this is just a minor compliance tweak, you’re already behind.
Your agency will tell you they’ve got this covered. If that’s true, ask them to show you their integrated attribution model across all four PESO Model© channels. Watch how quickly their confidence fades.
The Expanding Risk of Channel Dependence
Direct-to-consumer has been a pharma crutch for decades. Ten billion dollars in ad spend last year alone. Ten billion!
Just like anything else, the risks compound when you rely too heavily on one lever. And I get it. Paid media is easy to measure, and the results can make or break a new product launch.
But the U.S. and New Zealand are the only countries that even allow it. Everywhere else, pharma companies have learned to thrive without glossy ads. Which means some companies have a twenty-year head start on perfecting the playbook you’re about to need. When they compete with U.S. brands globally, they win.
The threat isn’t just regulatory fines. It’s the moment you stand in front of your board and explain why patient starts are down double digits while your rival’s are up. It’s the investor call where margin pressure suddenly has your name on it. It’s the Monday morning you realize the funnel you built on a single channel has evaporated.
And if you don’t move, you’re not just losing pipeline—you’re explaining to your board, your investors, and your CEO why your rivals are outpacing you on your watch.
The beauty of the PESO Model is that it was built for this exact kind of moment. When one channel falters, the others are already in place to absorb the shock.
It’s the operating advantage of an integrated system. And it’s why the CMOs who move first will take market share while everyone else scrambles.
If paid media suddenly becomes less persuasive—or more expensive—the dollars don’t vanish. They migrate.
Instead of pumping money into thirty-second TV spots that now spend half their time reading disclaimers, brands can redirect to precision targeting of healthcare providers, sponsorship of medical conferences, or placements in peer-reviewed journals.
Those aren’t just safer—they often generate three times the script lift compared to consumer ads.
But paid is just the first layer. Earned media picks up where paid leaves off.
Clinical trial results, medical journal coverage, and credible commentary from key opinion leaders create authority that can’t be legislated away.
A well-placed article in a respected outlet can drive five times more physician inquiries than a television campaign—and unlike ad spend, earned credibility compounds over time.
Beyond media coverage, shared media provides the authenticity that advertising can’t.
Patient communities, advocacy groups, and caregiver networks offer stories that resonate more deeply than any commercial.
According to the Edelman Trust Barometer, 92% of patients trust peer recommendations, compared to just 14% who trust pharmaceutical advertising.
When your story circulates in those circles, it’s no longer an ad. It’s a signal of trust. And guess who else uses those trust signals? That’s right! AI.
Finally, there’s the channel no regulator can touch: owned media. Patient portals, disease-education hubs, and clinical resource centers aren’t promotional gimmicks.
They’re transparent, educational platforms where patients spend real time. Educational content routinely delivers ten times the engagement of traditional ad creative, with the added benefit of building long-term trust.
The point isn’t to abandon paid media. It’s to stop pretending that paid can shoulder the whole load.
The PESO Model weaves the four channels together so that when policy, platform, or public opinion shifts, your strategy doesn’t collapse with it.
And thanks to today’s multi-touch attribution technology, PESO isn’t just a philosophy—it’s a measurable, optimizable strategy.
Brands with integrated PESO frameworks see 23% lower acquisition costs and 31% higher lifetime value. That’s the kind of performance metric your CFO—and your board—actually cares about.
The Trust Dividend
Too many marketers treat regulation as a nuisance. Smart CMOs recognize it as a stress test—and an opportunity. Healthcare has already shifted from “doctor knows best” to participation, where patients expect transparency and partnership.
That means disclosure-heavy ads aren’t just a compliance headache. They’re a public litmus test.
Does your brand look like it’s reluctantly obeying the law, or does it look like it was built to be upfront all along?
The difference isn’t cosmetic. It’s the difference between holding market share and explaining a double-digit drop in patient starts on your next earnings call.
Here’s where the PESO Model creates an unfair advantage. Earned mentions in medical journals, authentic patient stories in shared communities, and comprehensive resources in owned channels all reinforce the credibility that disclosure alone can’t carry.
Instead of scrambling to defend your reputation, you walk into the boardroom with numbers that show transparency turned into trust—and trust turned into pipeline.
Your competitors who keep clinging to paid-first strategies will look defensive, retrofitting disclosures onto campaigns that no longer work.
You’ll look proactive, patient-first, and—most importantly—like the only marketer in the room who anticipated what the market already demands.
The PESO Model Precedent
We’ve already seen what happens when the old playbook collapses. During the COVID vaccine rollout, Pfizer and Moderna didn’t build confidence with Super Bowl ads. They built it with medical spokespersons who became household names, with clinical data that hit headlines week after week, and with partnerships that gave their story credibility no commercial could buy.
That was earned and shared driving adoption when paid wasn’t even an option.
Look abroad and the story is even more clear.
In Europe, where direct-to-consumer advertising has been banned for decades, some pharma companies didn’t just survive. They dominated. And when those European brands compete globally, they bring that advantage with them.
Even here in the U.S., the split between adapters and laggards is obvious.
When the government briefly required drug price disclosures in 2019, some companies froze. Campaigns stalled, media dollars wasted, pipelines disrupted.
Others moved fast, bolstering owned channels with pricing explainers and leaning into earned media to frame the conversation.
Guess which group ended the year with stronger trust scores and steadier patient acquisition?
These are competitive realities. Every regulatory shift widens the gap between brands that treat the PESO Model as insurance and those that wait until the fire’s already burning.
The brands that move first don’t just survive the change. They seize the advantage their competitors handed them.
The PESO Model as Regulatory Insurance
The smart move isn’t to wait until your quarterly numbers crater or until your board asks why patient starts are down double digits.
By then, you’re playing defense. The time to act is before enforcement turns into attrition.
Start by auditing where your weight sits. For most pharma brands, the imbalance is glaring—paid still eats the lion’s share of budget even as its effectiveness erodes under regulation and skepticism.
That’s not resilience. That’s a liability.
PESO gives you cover on two fronts.
First, diversification. When one channel is kneecapped, the others are already carrying weight.
Second, foresight. Integrated measurement means you don’t just track TV GRPs or digital impressions. You track how patients move—from awareness to interest to perception to consideration to conversion—across all four channels.
Unlike single-channel metrics, the PESO Model gives you a full-funnel view of what’s working, what’s stalling, and where to double down.
And don’t kid yourself that you have time. Enforcement has already started. By the end of this year, the market will have split into two groups: the brands that built PESO infrastructure early and look like they planned for this, and the brands that are scrambling to retrofit trust into campaigns that no longer work.
The former will be taking your market share while you’re still rewriting disclaimers.
Complex? Yes. But complexity is the moat. It’s what separates the marketers the board trusts with growth from the ones they replace when the numbers slip.
The Six-Month Window
This new reality won’t kill pharma marketing—it will kill lazy pharma marketing.
What survives—and thrives—are strategies built on multiple pillars. When paid stumbles, earned, shared, and owned keep the message moving. When commercials sound more like disclaimers than persuasion, transparency across channels becomes a competitive advantage.
The PESO Model has always been the smarter play. Now it’s the only play.
The decision before you is timing: adopt it proactively and lead, or wait until the market leaves you reacting. And if you think this won’t show up in your board deck, think again—activist investors and proxy advisors are already scrutinizing marketing ROI with sharper eyes than regulators.
And make no mistake—your competitors aren’t waiting. Major pharma brands are shifting budgets, standing up earned media war rooms, and hiring shared-media specialists.
If pharma companies implement this now, they’ll have their PESO infrastructure in place by January and be taking market share by March.
The question isn’t whether you need the PESO Model. It’s whether you’ll be fast enough to secure the talent and partners before your competitors lock them up.
© 2025 Spin Sucks. All rights reserved. The PESO Model is a registered trademark of Spin Sucks.
